Introduction Tamoxifen (TMX) shows promise in treating breast cancer, but it faces challenges such as poor solubility, instability, and incomplete release when targeting tumors. Additionally, TMX therapy’s toxicity is a critical issue in breast cancer treatment. This study aimed to assess the impact of hyaluronic acid (HA)-coated TMX-loaded solid lipid nanoparticles (HA-TMX-SLNs) on MCF7 breast cancer cells. Methods Solid lipid nanoparticles (SLNs) were prepared using hot homogenization. The HA-TMX-SLNs and TMX-SLNs were characterized and evaluated through transmission electron microscopy (TEM). Cytotoxicity was assessed using the MTT assay, and Western blot analysis was utilized to identify key factors in the cell cycle and apoptosis. Results The nanoparticles (HA-TMX-SLNs) demonstrated approximately 55% loading efficiency after 100 h. HA-TMX-SLNs exhibited lower cytotoxicity in MCF7 cells compared to other treatments. Significant decreases in expression levels of cyclin-dependent kinase (CDK) 4, Cyclin D1, CDK2, and Bcl2 were observed after treatment with HA-TMX-SLNs, along with an increase in cleaved/procaspase-7. Discussion The in vitro release study showed that HA-coated SLNs consistently released the drug into the media under controlled conditions. Furthermore, HA-TMX-SLNs exhibited cytotoxic effects, increasing apoptosis and inhibiting cancer cell proliferation. These findings suggest that HA-TMX-SLNs effectively deliver TMX to breast cancer cells.

01 Aug 2025·Journal of Colloid and Interface Science

Incorporating nickel-substituted polyoxometalate into a photoactive metal–organic framework for efficient photodegradation of thiamethoxam insecticide

Article

Author: Yu, Jun-Hao ; Lu, Jia-Chang ; Chen, Ze-Lin ; Wang, Rui ; Lu, Bing-Bing ; Zhao, Qing-Yun ; Fu, Ying ; Ye, Fei ; Kong, Xiang-Chuan

Hydrogen bonding enhances the interactions between host and guest molecules and facilitates electron transfer between them. In this study, a series of hydrogen-bonded Z-scheme photocatalysts were prepared via impregnation. Nickel (Ni)-substituted polyoxometalate (POM) Na₆K₄[Ni₄(H₂O)₂(PW₉O₃₄)₂]∙32H₂O (Ni₄P₂) was anchored within the pores of Zr₆(μ₃-OH)₈(-OH)₈(TBAPy)₂ (NU-1000) via hydrogen bonding interactions (H₄TBAPy = 1,3,6,8-tetrakis(p-benzoic acid)pyrene). Hydrogen bonding not only effectively prevented the leakage of Ni₄P₂ from NU-1000 pores but also facilitated electron transfer from Ni₄P₂ to NU-1000. The optimized 0.3-Ni₄P₂@NU-1000 photocatalyst delivered remarkable performance toward thiamethoxam (TMX) photodegradation, achieving a degradation efficiency of 75.1 % after 120 min. The effects of the photocatalyst dose, pH, coexisting ions, and water sample on TMX degradation were investigated. Radical scavenging experiments and electron spin resonance data revealed that superoxide radicals and holes are the primary species responsible for photodegradation. Moreover, the reaction mechanism and degradation pathways of TMX were thoroughly investigated. Density functional theory calculations confirmed that TMX is adsorbed onto Ni₄P₂ via hydrogen bonding, structurally changing TMX and increasing its susceptibility to degradation. Chia seed growth experiments and Toxicity Estimation Software Tool analysis indicated that the aquatic toxicities of TMX intermediates and final products are lower than that of the undegraded TMX. This study advances the application of substituted POM-modified NU-1000 for treating TMX-contaminated wastewater.

01 Jun 2025·Toxicology Reports

Toxicological impact of Thiamethoxam on adult male rats: Histopathological, biochemical, and oxidative DNA damage assessment

Article

Author: Gaber, Yasmin M ; Issa, Sahar Y ; Rahman, S M Abdel ; Soliman, Nada A H

BackgroundThiamethoxam (TMX), a widely used second-generation neonicotinoid insecticide, has raised concerns due to its toxic effects on non-target species, including mammals. Its prolonged use is associated with hepatotoxicity, nephrotoxicity, and reproductive damage.ObjectivesThis study evaluates the dose-dependent biochemical, histopathological, and genetic toxic effects of TMX in male albino rats, emphasizing its impact on the liver, kidney, and reproductive systems.Materials and methodsForty male Wistar albino rats were assigned to control and three experimental groups treated with TMX at 26, 39, and 78 mg/kg/day over eight weeks. Key biochemical markers such as Alanine transaminase (ALT), Aspartate transaminase (AST), urea, creatinine and oxidative stress indicators (Catalase (CAT), Glutathione (GSH), Malondialdehyde (MDA), and reproductive parameters (testosterone, sperm count, and motility) were analyzed. Histopathological examination of the liver, kidney, and testes was performed, alongside evaluation of Deoxyribonucleic Acid (DNA) damage in testicular tissue.ResultsTMX exposure caused significant dose-dependent increases in liver and kidney function markers and oxidative stress. Reproductive toxicity was evident, with reduced testosterone levels, impaired sperm parameters, and histopathological damage to testicular tissue. Notably, TMX induced oxidative DNA damage in testicular tissue, as indicated by increased levels of 8-hydroxy-2'-deoxyguanosine.ConclusionsThis study highlights TMX's systemic toxicity in a dose-dependent manner, with oxidative stress and DNA damage as key mechanisms. The findings underscore the need for stricter regulatory measures and further exploration of protective strategies to mitigate TMX-induced toxicity.

News (Medical) associated with Manganescan (QurCan Therapeutics)

17 May 2021

·www.biospace.com

Nanology Labs Secures $3 Million in Oversubscribed Seed Round

May 17, 2021 10:00 UTC TORONTO--(BUSINESS WIRE)-- Nanology Labs, an IND-stage company developing next generation nanomedicines to conquer cancer, announced today that its seed capital raise was oversubscribed at $3M. The round was led by FACIT with co-investors Creative Destruction Lab Angels, Ontario Brain Institute, Ontario Center of Innovation, and MEDTEQ. The capital will advance development of T-MX (aka Manganescan), a smart nanomedicine designed to overcome tumor hypoxia, a common cause of resistance in cancer treatment. The financing is timely as T-MX completes GLP-toxicology and GMP-manufacturing in readiness for a Ph1/2 study in patients with oligometastatic brain cancer, planned to start at the Princess Margaret Cancer Center, recognized internationally for expertise in tumor hypoxia. “Nanoparticles derived from our platform technology are actively transported into cells and across the blood-brain barrier. Our lead product, T-MX, accumulates in cancer cells, where it becomes detectable by MR-imaging and generates oxygen molecules that reprogram hypoxic tumors from cold to hot. This, in turn, boosts immunogenic cell death and greatly sensitizes solid tumors to destruction by radio, chemo and immunotherapy.” says Dr. Mohammad Amini, CEO and co-founder of Nanology Labs, “Extensive safety, efficacy, and manufacturing studies have de‑risked T-MX to the extent that we are confident it could provide greater therapeutic efficacy and longer patient survival, offering healthcare professionals a potentially curative therapy across a broad range of cancers.” About Nanology Labs Nanology Labs is leveraging a patented polymer-lipid platform technology to develop unique nanoparticles that are actively transported into cells where they release therapeutic and diagnostic payloads including proteins, nucleic acids, drugs, and imaging agents. Groundbreaking research on T-MX has been reported in leading scientific journals including the Journal of the National Cancer Institute, Cancer Research, Advanced Functional Materials, and ACS Nano. View source version on businesswire.com: Contacts Nanology Labs Media Contact John Reid, EVP Business Development, j.reid@nanologylabs.com Source: Nanology Labs View this news release online at:

Immunotherapy

100 Deals associated with Manganescan (QurCan Therapeutics)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Head and Neck Neoplasms	Preclinical	Canada	QurCan Therapeutics Inc.	05 Jun 2024
Prostatic Cancer	Preclinical	Canada	QurCan Therapeutics Inc.	05 Jun 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Manganescan (QurCan Therapeutics)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation